olivLaw · US equity research
Dr. Reddy's Laboratories Limited RDY
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
Dr. Reddy's Laboratories is a global pharmaceutical company focused on generics, expanding into biosimilars and consumer healthcare, with the aim of improving access to affordable medicines. Its total revenue reached Rs. 335,933 million in fiscal 2026, and Global Generics accounted for about 89% of that total.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Dr. Reddy's Laboratories Limited (RDY) stock was 14.77 USD (+3.29% on the day), with market capitalisation 12.3 bn USD, P/E 18.7 on diluted EPS of 0.79 USD over the last 12 months, dividend yield 270.82%, beta 0.43, 52-week range 11.38–15.38 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 82.5
- overbought (≥ 70)
- Bollinger (20, 2)
- 12.05 – 14.76
- above the upper band · %B 1.00 · band width 20.2%
- SMA 50 / 200
- 12.67 / 13.24
- mixed trend
- MACD (12, 26, 9)
- 0.52 / 0.41
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +19.9% | −1.1% | +21.0 pp | — |
| 3 months | +21.7% | −0.5% | +22.1 pp | — |
| 6 months | +9.7% | +4.4% | +5.3 pp | — |
| Year to date | +5.2% | +12.3% | −7.1 pp | — |
| 1 year | +9.7% | +13.5% | −3.9 pp | −9.2% |
| 3 years | +14.9% | +76.4% | −61.5 pp | +50.7% |
| 5 years | +16.5% | +63.7% | −47.2 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 100 percentile of its own 8-quarter history (min 3.5, median 5.6, max 16.7; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.2 bn | 2.2 bn | 2.3 bn | 2.6 bn | 2.8 bn | 3.0 bn | 3.4 bn | 3.8 bn |
| Revenue YoY | unavailable | +2.0% | +4.1% | +12.0% | +8.9% | +5.9% | +12.0% | +13.8% |
| Net income | 151.0 m | 272.0 m | 259.0 m | 236.0 m | 311.0 m | 548.0 m | 668.0 m | 663.0 m |
| Net income YoY | unavailable | +80.1% | −4.8% | −8.9% | +31.8% | +76.2% | +21.9% | −0.7% |
| Diluted EPS | 0.91 | 1.64 | 1.56 | 1.52 | 1.87 | 3.30 | 4.01 | 0.79 |
| Diluted EPS YoY | unavailable | +80.2% | −4.9% | −2.6% | +23.0% | +76.5% | +21.5% | −80.3% |
| net % | 6.9% | 12.2% | 11.2% | 9.1% | 11.0% | 18.3% | 19.9% | 17.4% |
| Free cash flow | 134.0 m | 314.0 m | 332.0 m | 355.0 m | 177.0 m | 578.0 m | 348.0 m | 223.0 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Mar 2025
- Cash
- 172.0 m USD
- Financial debt
- 537.0 m USD
- Net debt
- 365.0 m USD
- Equity
- 3.9 bn USD
- Total assets
- 5.8 bn USD
- Debt / equity
- 0.14x
- Current ratio
- 1.92x
- ROE
- 18.1%
- ROA
- 12.7%
- FCF margin
- 5.9%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 2.3 bn | 2.6 bn | 2.8 bn | 3.0 bn | 3.4 bn | 3.8 bn | SEC (XBRL)· 06 Jun 2025verified |
| Cost of revenue | 1.1 bn | 1.2 bn | 1.3 bn | 1.3 bn | 1.4 bn | 1.6 bn | SEC (XBRL)· 06 Jun 2025verified |
| Gross profit | 1.2 bn | 1.4 bn | 1.5 bn | 1.7 bn | 2.0 bn | 2.2 bn | SEC (XBRL)· 06 Jun 2025verified |
| Research & development | 204.0 m | 226.0 m | 230.0 m | 236.0 m | 274.0 m | 320.0 m | SEC (XBRL)· 06 Jun 2025verified |
| Operating income | 212.0 m | 332.0 m | 389.0 m | 695.0 m | 813.0 m | 842.0 m | SEC (XBRL)· 06 Jun 2025verified |
| Interest expense | 13.0 m | 13.0 m | 13.0 m | 17.0 m | 21.0 m | 33.0 m | SEC (XBRL)· 06 Jun 2025verified |
| Pre-tax income | 239.0 m | 361.0 m | 426.0 m | 734.0 m | 862.0 m | 900.0 m | SEC (XBRL)· 06 Jun 2025verified |
| Income tax | -19.0 m | 125.0 m | 115.0 m | 186.0 m | 194.0 m | 229.0 m | SEC (XBRL)· 06 Jun 2025verified |
| Net income | 259.0 m | 236.0 m | 311.0 m | 548.0 m | 668.0 m | 663.0 m | SEC (XBRL)· 06 Jun 2025verified |
| Diluted EPS | 1.56 | 1.52 | 1.87 | 3.30 | 4.01 | 0.79 | SEC (XBRL)· 06 Jun 2025verified |
| Weighted average diluted shares | 166.1 m | 166.3 m | 166.3 m | 831.9 m | 833.5 m | 834.2 m | SEC (XBRL)· 06 Jun 2025verified |
| Dividend per share | 20.00 | 25.00 | 25.00 | 30.00 | 40.00 | 40.00 | SEC (XBRL)· 06 Jun 2025verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 27.0 m | 203.0 m | 196.0 m | 70.0 m | 85.0 m | 172.0 m | SEC (XBRL)· 06 Jun 2025verified |
| Receivables | 667.0 m | 679.0 m | 880.0 m | 882.0 m | 963.0 m | 1.1 bn | SEC (XBRL)· 06 Jun 2025verified |
| Inventories | 465.0 m | 621.0 m | 671.0 m | 592.0 m | 763.0 m | 832.0 m | SEC (XBRL)· 06 Jun 2025verified |
| Current assets | 1.7 bn | 2.0 bn | 2.4 bn | 2.5 bn | 3.0 bn | 2.9 bn | SEC (XBRL)· 06 Jun 2025verified |
| Property, plant & equipment, net | 694.0 m | 781.0 m | 819.0 m | 809.0 m | 923.0 m | 1.1 bn | SEC (XBRL)· 06 Jun 2025verified |
| Goodwill | 53.0 m | 62.0 m | 58.0 m | 52.0 m | 51.0 m | 138.0 m | SEC (XBRL)· 06 Jun 2025verified |
| Intangibles (excl. goodwill) | 367.0 m | 487.0 m | 359.0 m | 375.0 m | 443.0 m | 1.1 bn | SEC (XBRL)· 06 Jun 2025verified |
| Total assets | 3.1 bn | 3.6 bn | 3.9 bn | 3.9 bn | 4.7 bn | 5.8 bn | SEC (XBRL)· 06 Jun 2025verified |
| Accounts payable | 221.0 m | 325.0 m | 337.0 m | 322.0 m | 371.0 m | 417.0 m | SEC (XBRL)· 06 Jun 2025verified |
| Short-term debt | 218.0 m | 316.0 m | 357.0 m | 90.0 m | 153.0 m | 445.0 m | SEC (XBRL)· 06 Jun 2025verified |
| Long-term debt | 17.0 m | 86.0 m | 76.0 m | 16.0 m | 72.0 m | 92.0 m | SEC (XBRL)· 06 Jun 2025verified |
| Current liabilities | 966.0 m | 1.1 bn | 1.2 bn | 1.0 bn | 1.2 bn | 1.5 bn | SEC (XBRL)· 06 Jun 2025verified |
| Total liabilities | 1.0 bn | 1.3 bn | 1.3 bn | 1.1 bn | 1.3 bn | 1.8 bn | SEC (XBRL)· 06 Jun 2025verified |
| Equity | 2.1 bn | 2.4 bn | 2.5 bn | 2.8 bn | 3.4 bn | 3.9 bn | SEC (XBRL)· 06 Jun 2025verified |
| Shares outstanding at year end | 166.2 m | 166.3 m | 166.4 m | 166.5 m | 166.8 m | 834.5 m | SEC (XBRL)· 06 Jun 2025verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 396.0 m | 488.0 m | 370.0 m | 716.0 m | 545.0 m | 545.0 m | SEC (XBRL)· 06 Jun 2025verified |
| Capex | 64.0 m | 133.0 m | 193.0 m | 138.0 m | 197.0 m | 322.0 m | SEC (XBRL)· 06 Jun 2025verified |
| Free cash flow | 332.0 m ≈ | 355.0 m ≈ | 177.0 m ≈ | 578.0 m ≈ | 348.0 m ≈ | 223.0 m ≈ | SEC (XBRL)· 06 Jun 2025derived |
| Investing cash flow | -65.0 m | -310.0 m | -348.0 m | -503.0 m | -483.0 m | -682.0 m | SEC (XBRL)· 06 Jun 2025verified |
| Financing cash flow | -334.0 m | -4.0 m | -32.0 m | -327.0 m | -45.0 m | 222.0 m | SEC (XBRL)· 06 Jun 2025verified |
| Dividends paid | 52.0 m | 57.0 m | 55.0 m | 61.0 m | 80.0 m | 78.0 m | SEC (XBRL)· 06 Jun 2025verified |
| Share repurchases | — | — | 0 | — | — | — | SEC (XBRL)· 27 Jun 2022verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 55 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 12.3 bn USD
Key indicators
Coverage and freshness
The data is older than the freshness threshold.
Score by group
- Valuation49
- Balance sheet97
- Quality52
- Growth44
- Returns45
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 4.11 – 706.90 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)4.11 – 6.58 (Mid 5.07)WACC 9.1% · starting FCFF 247.6 m USD · terminal value share of EV 74%The WACC × g sensitivity gives the method's bounds; these are not probabilities.Reverse DCF: no growth between −30% and +40% justifies the price
- Peers: EV/EBITDAunavailable · input data missing
- Peers: P/E11.81 – 34.48 (Mid 23.03)14 companies used · median multiple 29.1x · quartiles 14.9x – 43.6xABBV, ABT, ALNY, AUPH, BMY, JNJ, LLY, NATR, PFE, REGN, RPRX, UTHR, VRTX, ZTS
- Dividend discount (DDM)525.64 – 706.90 (Mid 602.94)
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Neutral profile · Score 55/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 16.1% | 67 (vs peers) | 13% |
| Net margin · Quality | 17.4% | 74 (vs peers) | 8% |
| FCF conversion · Quality | 33.6% | 5 (on a fixed band) | 8% |
| Revenue CAGR 3Y · Growth | 10.5% | 87 (on a fixed band) | 11% |
| EPS CAGR 3Y · Growth | -25.0% | 0 (on a fixed band) | 11% |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | 25.5x | 100 (on a fixed band) | 8% |
| Current ratio · Balance sheet | 1.9x | 93 (on a fixed band) | 5% |
| P/E (TTM) · Valuation | 18.7x | 71 (vs peers) | 13% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | 1.8% | 23 (on a fixed band) | 11% |
| Shareholder yield (distributions) · Returns | 0.6% | 9 (on a fixed band) | 8% |
| Payout ratio (FCF) · Returns | 35.0% | 100 (on a fixed band) | 5% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet97/100 · 2/3 factors with a value
- Growth44/100 · 2/2 factors with a value
- Quality52/100 · 3/3 factors with a value
- Returns45/100 · 2/2 factors with a value
- Valuation49/100 · 2/3 factors with a value
Memo
DR. REDDY’S LABORATORIES LIMITED (RDY). Latest full fiscal year: 2025; data up to 2025-03-31.
Figures computed from the financial statements: revenue 3.8 bn USD in 2025; YoY growth 13.8%; net margin 17.4%; ROE 17.0%.
The estimated value range is 11.81–34.48 USD per share (median of 3 methods, agreement: low); assumptions are illustrative. Against the central value of 23.03 USD, the price of 14.77 USD leaves a potential of 55.9% (value / price − 1) and a margin of safety of 35.9% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 55/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 17.4%
- Revenue CAGR 3Y: 10.5%
- Interest coverage: 25.5x
- Current ratio: 1.9x
- P/E (TTM): 18.7x
- Payout ratio (FCF): 35.0%
What contradicts it
- FCF conversion: 33.6%
- EPS CAGR 3Y: -25.0%
- FCF yield: 1.8%
- Shareholder yield (distributions): 0.6%
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): Net debt / EBITDA, EV/EBITDA.
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LLYEli Lilly And Company | 1,334.0 bn | 46.0 | 86.1% | 31.9% | +44.7% | +32% / +140% |
| JNJJohnson & Johnson | 665.2 bn | 41.9 | 20.0% | 16.2% | +6.0% | +34% / +79% |
| ONCBeone Medicines Ltd. | 558.4 bn | 869.9 | 14.7% | 10.7% | +40.2% | +11% / +102% |
| ABBVAbbVie Inc. | 521.1 bn | 50.7 | — | 15.7% | +8.6% | +29% / +107% |
| MRKMerck & Co., Inc. | 370.7 bn | 154.7 | 5.1% | 3.6% | +1.3% | +43% / +47% |
| ABTAbbott Laboratories | 200.1 bn | 43.0 | 9.2% | 9.7% | +5.7% | −10% / +11% |
| PFEPfizer Inc | 175.5 bn | 43.9 | 4.4% | 6.3% | −1.6% | +20% / +1% |
| VRTXVertex Pharmaceuticals Inc | 139.2 bn | 35.3 | 20.8% | 30.7% | +8.9% | +27% / +55% |
| BMYBristol-Myers Squibb Company | 131.2 bn | 14.2 | 44.1% | 18.5% | −0.2% | +30% / +30% |
| TEVATeva Pharmaceutical Industries Limited | 48.8 bn | 97.4 | 6.6% | 3.6% | +4.3% | +56% / +326% |
| ZTSZoetis Inc. | 36.9 bn | 14.7 | 64.4% | 27.5% | +2.3% | −30% / −50% |
| ROIVRoivant Sciences Ltd. | 27.6 bn | — | -6.2% | -3,535.0% | −71.6% | +84% / +300% |
| RPRXRoyalty Pharma plc | 26.2 bn | 47.7 | 6.9% | 25.7% | +5.1% | +69% / +150% |
| UTHRUnited Therapeutics Corporation | 25.9 bn | 23.0 | 19.1% | 38.6% | +10.6% | +25% / +154% |
| INSMInsmed Inc | 24.1 bn | — | -72.5% | -39.9% | +66.7% | −47% / +340% |
| VTRSViatris Inc. | 22.1 bn | — | -23.6% | -23.9% | −3.0% | +80% / +109% |
| ALNYAlnylam Pharmaceuticals, Inc. | 21.6 bn | 8.1 | 126.6% | 52.8% | +65.2% | −64% / −4% |
| RDYDr. Reddy’s Laboratories Limited | 12.3 bn | 18.7 | 17.0% | 17.4% | +13.8% | +10% / +15% |
| ORKAOruka Therapeutics, Inc. | 6.7 bn | — | -18.2% | — | unavailable | +237% / +364% |
| IONSIonis Pharmaceuticals, Inc. | 6.7 bn | — | -105.5% | -64.7% | +33.8% | −51% / −19% |
| IDYAIDEAYA Biosciences, Inc. | 3.1 bn | — | -38.5% | -1,149.6% | +3,024.4% | −9% / +3% |
| RADXRadiopharm Theranostics Limited | 3.1 bn | — | -109.2% | -1,055.3% | +1,114.3% | −81% / unavailable |
| AUPHAurinia Pharmaceuticals Inc. | 2.3 bn | 7.5 | 61.4% | 97.7% | +20.4% | +6% / +98% |
| QUREuniQure N.V. | 1.6 bn | — | -89.0% | -1,154.8% | −40.6% | −16% / +240% |
| URGNUroGen Pharma Ltd. | 1.4 bn | — | — | -26.3% | +21.4% | −0% / +118% |
1- and 3-year price returns: for RDY from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 9.31 Total return -33% · Per year -33% | 16.41 Total return 17% · Per year 17% | 24.65 Total return 74% · Per year 74% |
| 3 years | 10.15 Total return -17% · Per year -6% | 20.03 Total return 55% · Per year 16% | 32.88 Total return 148% · Per year 35% |
| 5 years | 11.07 Total return -0% · Per year -0% | 24.45 Total return 102% · Per year 15% | 43.85 Total return 245% · Per year 28% |
- Exit P/E± 5.01
- Net margin± 3.50
- Annual revenue growth± 2.72
- Annual dilution± 0.29
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 29 May 2026; since then the company filed 6-K (04 Nov 2026), 6-K (29 Oct 2026), 6-K (26 Oct 2026), 6-K (23 Oct 2026).
In brief
Dr. Reddy's Laboratories is a global pharmaceutical company focused on generics, expanding into biosimilars and consumer healthcare, with the aim of improving access to affordable medicines. Its total revenue reached Rs. 335,933 million in fiscal 2026, and Global Generics accounted for about 89% of that total 1.
SWOT
Strengths
Weaknesses
Opportunities
Threats
- Competitive pressure in generics may reduce prices and margins, especially for products with many competitors 1.
- Regulatory changes in India and other countries may require adjustments to marketing and operating models 1.
- Rebate, return and chargeback mechanisms can reduce gross revenue if contract terms worsen 1.
Risks
- Price pressure in North Americahigh
Revenue in this region declined, and further generic price cuts could continue to weigh on segment results 1.
- Acquisition integrationmedium
The NRT portfolio is being integrated in phases, and delays or unexpected costs could reduce the expected benefits 1.
- Marketing regulation in Indiamedium
The Uniform Code for Pharmaceutical Marketing Practices became mandatory, and further regulatory changes may require changes to commercial practices 1.
- Capital commitmentsmedium
Contractual commitments for new capacity are significant, and delayed execution could reduce the return on those investments 1.
- Biosimilar development risklow
Biosimilar partnerships share development risk, but products may face approval delays or competition from other manufacturers 1.
Investment thesis
What would need to be true (bull case)
- If the Global Generics segment keeps growing and the NRT integration produces synergies, the company could diversify revenue beyond traditional generics 1.
- Sales growth in the Indian market, which outpaced the market, suggests a solid position in the domestic segment 1.
- Biosimilar partnerships give access to higher-value categories without bearing the full development risk alone 1.
What would break the thesis
- If price pressure in North America persists, segment revenue could remain below expectations 1.
- Large capital expenditure and contractual commitments could limit available cash flows if revenue slows 1.
- Integrating several acquisitions across countries could face difficulties, reducing the benefits of the consumer healthcare strategy 1.
What to watch
- Trend in North America revenue and margins within Global Genericsnext 10-K
- Progress in integrating the NRT portfolio acquired from Haleon2027
- Execution of contractual capital commitments for new capacitynext 10-K
- Biosimilar launches under the Alvotech and Shanghai Henlius partnerships2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 29 May 2026; since then the company filed 6-K (04 Nov 2026), 6-K (29 Oct 2026), 6-K (26 Oct 2026), 6-K (23 Oct 2026).
The business
Founded in 1984 in India, the company reports three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others 1. Global Generics includes branded and generic formulations, the biologics business, and, since September 2024, the nicotine replacement therapy portfolio acquired from Haleon outside the United States 1. PSAI covers active pharmaceutical ingredients and pharmaceutical services, while Others includes Aurigene Oncology and proprietary products 1.
The strategy aims to strengthen the core generics business while expanding into consumer healthcare and biosimilars through internal development, partnerships and selective acquisitions 1. The company entered a partnership with Nestlé Health Science India for nutritional and wellness products and expanded into biosimilars with Alvotech and Shanghai Henlius Biotech 1. Capital expenditures were Rs. 36,715 million in fiscal 2026, mainly for manufacturing and R&D facilities 1.
Key markets are the United States, India, Russia and other countries of the former Soviet Union, and Europe 1. The company says it expects to fund its capital commitments from internal operating cash flows and existing investments 1.
Segments
Market context
In India, the company was the 10th largest pharmaceutical company in fiscal 2026, with a 3.2% market share according to IQVIA, and its secondary sales grew faster than the market 1. The company notes that India's regulatory framework, including the Uniform Code for Pharmaceutical Marketing Practices made mandatory from March 2024, may require adjustments 1.
Regulated markets such as the United States and Europe remain essential for the generics segment, and the company sees development needs converging across regulated and less regulated markets 1. If price pressure or regulatory changes intensify, the impact could be felt mainly in North America, where revenue declined 1.
Trends
- Expansion into consumer healthcaretailwind
The acquisition of the Haleon NRT portfolio and the Nestlé Health Science India partnership point to a focus on OTC and wellness products that could diversify revenue if integration proceeds in phases 1.
- Growth of biosimilarstailwind
Partnerships for denosumab and daratumumab allow entry into complex, higher-value categories while reducing development risk, but they require continued investment 1.
- Price pressure in genericsheadwind
The company points to lower North America revenue and to rebate, returns and chargeback mechanisms that can reduce gross revenue in markets with intense competition 1.
- High capital investmentmixed
Capital expenditure has risen in recent years and contractual commitments for new capacity are significant, which may require steady cash flows 1.
Competitive position
In India, the company competes with several players, including Cipla, Sun Pharmaceutical, Zydus, Lupin, Glenmark, Torrent and Mankind, depending on therapeutic category 1. Competition varies by category, dosage strength and delivery, and pressure is higher in volume segments 1.
In international markets the company cites competition in generics and biosimilars, and its stated advantages are vertical integration and first-to-market launches 1. The source does not provide a quantitative comparison of market shares in external markets 1.
- Cipla Limited
Competitor in Indian formulations, named in the report 1.
- Sun Pharmaceutical Industries Limited
Competitor in the Indian formulations market, named in the report 1.
- Zydus Lifesciences Limited
Competitor in the Indian market across several therapeutic categories 1.
- Lupin Limited
Competitor in the Indian formulations market, named in the report 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report (foreign issuer)04 Nov 2026
- Current report (foreign issuer)29 Oct 2026
- Current report (foreign issuer)29 Oct 2026
- Current report (foreign issuer)26 Oct 2026
- Current report (foreign issuer)26 Oct 2026
- Current report (foreign issuer)23 Oct 2026
- Current report (foreign issuer)23 Oct 2026
- Current report (foreign issuer)23 Oct 2026
- Current report (foreign issuer)23 Oct 2026
- Current report (foreign issuer)21 Oct 2026
Sources
- [1] Form 20-F, fiscal year ended 2026-03-31 · SEC / Dr. Reddy's Laboratories Limited · 29 May 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.